According to the results of Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) therapy in HER2-positive BC patients, women showing a pCR have a significantly better overall survival rate than those almost showing a pCR [3,5]. The gene discussed is ERBB2; the disease is breast carcinoma.